Prenatal diagnosis in human immunodeficiency virus-infected women: A new screening program for chromosomal anomalies

被引:23
作者
Coll, O [1 ]
Suy, A
Hernandez, S
Pisa, S
Lonca, M
Thorne, C
Borrell, A
机构
[1] IDIBAPS, Inst Clin Ginecol, Serv Malad Infect, Barcelona, Spain
[2] IDIBAPS, Hosp Clin, Barcelona, Spain
[3] UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England
关键词
human immunodeficiency virus; prenatal diagnosis; vertical transmission; amniocentesis;
D O I
10.1016/j.ajog.2005.06.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: This study was undertaken to describe a new prenatal diagnosis program among human immunodeficiency virus (HIV)-infected women, and the perinatal outcome of this program's application over a more than 2-year period. Study design: From June 2000 to December 2003, all HIV-infected women who were booked into the antenatal clinic before 20 weeks were offered a screening for chromosomal anomalies, with midtrimester amniocentesis in the tests that were positive. Results: A total of 116 pregnancies (including 3 sets of twins) were seen: 96 women were offered and accepted screening for chromosomal anomalies. Thirteen pregnancies had a positive screening test and amniocentesis was performed in 10 at median 16.5 gestational weeks: a trisomy 21 and a monosomy X were diagnosed. No vertical transmissions were documented by age 6 months in the 6 liveborn infants who underwent amniocentesis. Conclusion: A program of prenatal diagnosis for chromosomal anomalies appears to be effective when applied to HIV-infected women, although safety remains to be proven. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:192 / 198
页数:7
相关论文
共 18 条
[1]  
[Anonymous], 2004, REP GLOB AIDS EP
[2]   First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional study [J].
Borrell, A ;
Casais, E ;
Fortuny, A ;
Farre, MT ;
Gonce, A ;
Sanchez, A ;
Soler, A ;
Cararach, C ;
Vanrell, JA .
PRENATAL DIAGNOSIS, 2004, 24 (07) :541-545
[3]  
Bucceri AM, 2001, ACTA OBSTET GYN SCAN, V80, P82, DOI 10.1080/791201840
[4]   Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission - A randomized trial [J].
Dorenbaum, A ;
Cunningham, CK ;
Gelber, RD ;
Culnane, M ;
Mofenson, L ;
Britto, P ;
Rekacewicz, C ;
Newell, ML ;
Delfraissy, JF ;
Cunningham-Schrader, B ;
Mirochnick, M ;
Sullivan, JL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :189-198
[5]   The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive [J].
Einstein, FH ;
Wright, RL ;
Trentacoste, S ;
Gross, S ;
Merkatz, IR ;
Bernstein, PS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (03) :1004-1008
[6]  
Ferrero S, 2002, Minerva Ginecol, V54, P373
[7]  
GROSS SF, 1997, AM J HUM GENET, pA153
[8]  
Laguno M, 2004, AIDS, V18, pF27, DOI 10.1097/00002030-200409030-00003
[9]  
Maiques V, 2003, EUR J OBSTET GYN R B, V108, P137, DOI 10.1016/S0301-2115(02)00405-0
[10]  
Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661